

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT

RECEIPT OF THE FIRST PAYMENT IN RELATION TO THE DISPOSAL OF CDMO ASSETS

This announcement is made by Transcenta Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

References are made to (i) the announcement of the Company dated August 6, 2026, (ii) the circular of the Company dated August 25, 2026 (the “**Circular**”) and (iii) the poll results announcement of the Company dated September 9, 2026, in relation to, among other things, the disposal of the CDMO Assets to the Purchaser, a wholly owned subsidiary of WuXi Biologics, at an aggregate consideration of RMB190 million, subject to the adjustment mechanism as described in the Circular. Unless otherwise defined, capitalized terms used in this announcement have the same meanings as those defined in the Circular.

The board of directors of the Company (the “**Board**”) is pleased to announce that, as of the date of this announcement, the Group has received net after-tax First Payment of the Consideration, amounting to RMB95 million, from the Purchaser in accordance with the terms of the Asset Purchase Agreement. The proceeds received will be used to supplement the Group’s general working capital and the development of the Group’s pipeline.

As a result of the disposal of the CDMO Assets, the Group’s staff costs and operating expenses are expected to decline in 2027 compared to 2026. The handover of the CDMO Assets is proceeding, and the Company expects to receive additional proceeds before the end of 2026, subject to the relevant terms and conditions of the Asset Purchase Agreement.

Forward Looking Statement

This announcement may contain projections, estimates, forecasts, ambitions, targets, commitments, opinions, prospects, results, returns and forward-looking statements which can be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “anticipate”, “project”, “estimate”, “seek”, “intend”, “target”, “plan”, “believe”, “potential” or “reasonably possible” or the negatives thereof or other variations thereon or comparable terminology (together, “forward-looking statements”). Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct. There is no assurance that any forward-looking statements in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors.

Shareholders and potential investors should be noted that the completion of the Transaction and the receipt of the remaining portions of the Consideration are subject to fulfilment (or waiver) of certain conditions and may or may not occur. Shareholders and potential investors should exercise caution when dealing in the relevant securities of the Company.

By Order of the Board
Transcenta Holding Limited
Xueming Qian

Executive Director, Chairman and Chief Executive Officer

Hong Kong, October 20, 2026

As at the date of this announcement, the Board comprises (i) Dr. Xueming Qian as executive Director, chairman and chief executive officer; (ii) Dr. Li Xu and Dr. Han Sen Xu as non-executive Directors; and (iii) Mr. Jiasong Tang, Ms. Helen Wei Chen and Prof. Genhong Cheng as independent non-executive Directors.